Huaan Securities released a research report on April 17 stating that it gave Eddy Pharmaceuticals (688488.SH) a purchase rating. The main reasons for the rating include: 1) sales in Q4 improved significantly from quarter to quarter, and sales of ACC008 increased significantly; 2) the new structure of the company team, direct business+investment model to expand market penetration; 3) the expansion of HIV drugs on sale into hospitals, and the clinical promotion of integrase inhibitors. (Mainichi Keizai Shimbun)
华安证券4月17日发布研报称，给予艾迪药业（688488.SH）买入评级。评级理由主要包括：1）销售Q4环比季度改善明显，ACC008销售提升显著；2）公司团队全新架构，直营+招商模式扩大渗透市场；3）HIV在售药物扩大进院，整合酶抑制剂临床推进中。（每日经济新闻）
Huaan Securities released a research report on April 17 stating that it gave Eddy Pharmaceuticals (688488.SH) a purchase rating. The main reasons for the rating include: 1) sales in Q4 improved significantly from quarter to quarter, and sales of ACC008 in
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated